Since studies in nephrotic syndrome have demonstrated that the rituximab effect is lost with recovery of the CD19+ cell population (32), we will study the proportion of patients with CD19+ <1% at 1 month, 6 months, and 12 months in the rituximab arm of the study. The gene discussed is CD19; the disease is nephrotic syndrome.